Notably, co-treatment with 5-FU appeared to have minimal benefit in enhancing the antitumor effects of each inhibitor (Figures 5B, 5C and 5D), suggesting that HSP90 or Src blockade would effectively suppress growth, migration, and invasion of 5-FU resistant colon cancer cells. Here, SRC is linked to malignant colon neoplasm.